Menu
← Oncology Approval Tracker
FDA DECISION ·
Yescarta
axicabtagene ciloleucel · Kite Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy.
LAMPGEN ANALYSIS
Why it matters
This accelerated action extended CD19 CAR T therapy to a previously treated indolent lymphoma population.
What research teams should watch
Document histology and prior lines, and plan lead time for referral and cell manufacturing.
PRIMARY RECORDS